Tribune News Service
New Delhi, September 11
The Serum Institute of India on Thursday announced halting of India trials of the Oxford University-AstraZeneca COVID vaccine candidate till the global suspension on the process is revoked and the trials restarted.
Adar Poonawala-led SII, which is a manufacturing partner for the vaccine, today said: “We are reviewing the situation and pausing India trials till AstraZeneca restarts them. We are following DCGI's instructions and will not be able to comment further on the same. You can connect with DCGI for more updates on this front.”
The announcement of India pause of trials was announced by SII a day after Drug Controller General of India issued it a show-cause notice asking why permissions granted earlier for phase 2 and 3 human trials on Indian volunteers not be suspended in the light of new evidence of severe illness in a participant of the UK phase-3 trial of the vaccine.
AstraZeneca yesterday announced global halt of the ongoing phase-3 trials of the said vaccine after a participant developed a serious neurological illness whose source is being probed.
Most Read In 24 Hours
Don't MissView All
Russia vows to build on privileged strategic partnership with India
Describes India and China as 'friendly sovereign global cent...
Gujarat High Court quashes order seeking information on PM Modi’s degree, imposes Rs 25,000 cost on Kejriwal; BJP slams Delhi CM
In April 2016, the then CIC M Sridhar Acharyulu had directed...
Navjot Sidhu to be released from jail tomorrow, confirms ADGP-Prisons
He is serving time in a road rage case dating back to 1988
Home Minister Amit Shah speaks to Bengal governor over violence during Ram Navami procession
Clashes broke out between two groups in the Kazipara area of...
Ahead of Navjot Sidhu’s release, his wife shares emotional post; son says family wishes to sit and have food together
Sidhu’s team in a tweet confirmed his release on April 1